Radiosynthesis and In Vivo Evaluation of [11C]A1070722, a High Affinity GSK-3 PET Tracer in Primate Brain.

Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage (2002) 38.46

Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab (1990) 6.62

GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov (2004) 3.93

AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol (2004) 1.79

Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. Pharmacol Ther (2014) 1.77

Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacol Rev (2013) 1.52

Models and methods for derivation of in vivo neuroreceptor parameters with PET and SPECT reversible radiotracers. Nucl Med Biol (2001) 1.48

Alteration in kinase activity but not in protein levels of protein kinase B and glycogen synthase kinase-3beta in ventral prefrontal cortex of depressed suicide victims. Biol Psychiatry (2006) 1.48

Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes. Curr Pharm Des (2004) 1.30

The INIA19 Template and NeuroMaps Atlas for Primate Brain Image Parcellation and Spatial Normalization. Front Neuroinform (2012) 1.14

Low GSK-3beta immunoreactivity in postmortem frontal cortex of schizophrenic patients. Am J Psychiatry (2000) 1.07

Synthesis and ex vivo evaluation of carbon-11 labelled N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea ([11C]AR-A014418): a radiolabelled glycogen synthase kinase-3beta specific inhibitor for PET studies. Bioorg Med Chem Lett (2005) 1.07

The effects of neuropsychiatric drugs on glycogen synthase kinase-3 signaling. Neuroscience (2011) 1.05

Synthesis and in vivo validation of [O-methyl-11C]2-{4-[4-(7-methoxynaphthalen-1-yl)piperazin- 1-yl]butyl}-4-methyl-2H-[1,2,4]triazine-3,5-dione: a novel 5-HT1A receptor agonist positron emission tomography ligand. J Med Chem (2006) 1.02

Low GSK-3 activity in frontal cortex of schizophrenic patients. Schizophr Res (2001) 1.00

Glycogen synthase kinase-3beta, beta-catenin, and tau in postmortem bipolar brain. J Neural Transm (Vienna) (1999) 1.00

Glycogen synthase kinase-3 beta (GSK-3β) signaling: Implications for Parkinson's disease. Pharmacol Res (2015) 0.96

Current therapies and emerging targets for the treatment of diabetes. Curr Pharm Des (2001) 0.94

Towards the preparation of radiolabeled 1-aryl-3-benzyl ureas: Radiosynthesis of [(11)C-carbonyl] AR-A014418 by [(11)C]CO(2) fixation. Bioorg Med Chem Lett (2012) 0.94

Protein levels of β-catenin and activation state of glycogen synthase kinase-3β in major depression. A study with postmortem prefrontal cortex. J Affect Disord (2011) 0.93

Synthesis and evaluation of [(11)C]PyrATP-1, a novel radiotracer for PET imaging of glycogen synthase kinase-3β (GSK-3β). Nucl Med Biol (2014) 0.90

GSK-3 parameters in postmortem frontal cortex and hippocampus of schizophrenic patients. Schizophr Res (2004) 0.88

The first synthesis of [(11)C]SB-216763, a new potential PET agent for imaging of glycogen synthase kinase-3 (GSK-3). Bioorg Med Chem Lett (2010) 0.87

Glycogen Synthase Kinase-3 (GSK-3)-Targeted Therapy and Imaging. Theranostics (2016) 0.84

Synthesis and Initial in Vivo Studies with [(11)C]SB-216763: The First Radiolabeled Brain Penetrative Inhibitor of GSK-3. ACS Med Chem Lett (2015) 0.84

Glycogen synthase kinase (GSK)-3beta levels and activity in a neurodevelopmental rat model of schizophrenia. Brain Res Dev Brain Res (2003) 0.83

GSK-3beta gene expression in human postmortem brain: regional distribution, effects of age and suicide. Neurochem Res (2008) 0.83

The acute and chronic effects of combined antipsychotic-mood stabilizing treatment on the expression of cortical and striatal postsynaptic density genes. Prog Neuropsychopharmacol Biol Psychiatry (2010) 0.82

Pivotal role of glycogen synthase kinase-3: A therapeutic target for Alzheimer's disease. Eur J Med Chem (2015) 0.82

Radiosynthesis and preliminary PET evaluation of glycogen synthase kinase 3β (GSK-3β) inhibitors containing [(11)C]methylsulfanyl, [(11)C]methylsulfinyl or [(11)C]methylsulfonyl groups. Bioorg Med Chem Lett (2015) 0.79

AKT/GSK3β Signaling in Glioblastoma. Neurochem Res (2016) 0.78

Discovery of a Highly Selective Glycogen Synthase Kinase-3 Inhibitor (PF-04802367) That Modulates Tau Phosphorylation in the Brain: Translation for PET Neuroimaging. Angew Chem Int Ed Engl (2016) 0.78

Pretreatment by evodiamine is neuroprotective in cerebral ischemia: up-regulated pAkt, pGSK3β, down-regulated NF-κB expression, and ameliorated BBB permeability. Neurochem Res (2014) 0.78

Inhibition of Glycogen Synthase Kinase-3: An Emerging Target in the Treatment of Traumatic Brain Injury. J Neurotrauma (2016) 0.78

Anti-malarial and anti-inflammatory effects of Gleichenia truncata mediated through inhibition of GSK3β. Trop Biomed (2015) 0.77